EUVIMEDEUVIMED entdecken
Open Access

Impact of Angiotensin Blockade on Development of Chronic Lung Allograft Dysfunction

Spenser E January iD, Julie Hubbard, Keith A Fester, Casey A Dubrawka, Rodrigo Vazquez Guillamet, Hrishikesh S Kulkarni, Ramsey R Hachem

Journal of Pharmacy Practice · 2024

DOI: 10.1177/08971900231213699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy Practice, 2024. Verfasst von Spenser E January und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, USA. Hauptthemen laut MEDLINE: Lung Transplantation, Angiotensin-Converting Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The renin-angiotensin-aldosterone system (RAAS) is responsible for a multitude of physiological functions, including immunological effects such as promotion of TGF-β and upregulation of IL-6 and IL-8 which are also implicated in the development of chronic lung allograft dysfunction (CLAD). Blockade of the RAAS pathway in pre-clinical models has demonstrated a decrease in these cytokines and pulmonary neutrophil recruitment.

Objective

This study sought to evaluate whether use of RAAS inhibitor (RAASi) in lung transplant recipients impacted CLAD-free survival.

Methods

In this retrospective, single-center study, 35 lung transplant recipients who received a RAASi post-transplant were compared to 70 lung transplant recipients not exposed to a RAASi and were followed for up to 5 years post-transplant.

Results

The incidence of CLAD did not differ based on RAASi treatment (34.3% in RAASi vs 38.6%, P-value .668). This was confirmed with a multivariable Cox proportional hazards model with RAASi initiation as a time-varying covariate (RAASi hazard ratio of 1.01, P-value .986). Incidence of hyperkalemia and acute kidney injury were low in the RAASi group.

Conclusions

This study demonstrated no association between post-transplant RAASi use and decreased risk of CLAD development. RAASi were also well tolerated in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung TransplantationAngiotensin-Converting Enzyme InhibitorsHumansMaleRetrospective StudiesFemaleMiddle AgedAdultAllograftsRenin-Angiotensin SystemChronic DiseaseAngiotensin Receptor AntagonistsAgedPrimary Graft Dysfunction

Stichwörter der Autor:innen

lung transplantationrenin angiotensin aldosterone systemtransplant rejection

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor Antagonists

Autor:innen und Institutionen

  • Department of Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, USA.
  • Division of Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, USA.

ORCID-Profile: Spenser E January

Förderung

  • NHLBI NIH HHS

Zitieren

APA

January, S. E., Hubbard, J., Fester, K. A., Dubrawka, C. A., Vazquez Guillamet, R., Kulkarni, H. S., & Hachem, R. R. (2024). Impact of Angiotensin Blockade on Development of Chronic Lung Allograft Dysfunction. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900231213699

Vancouver

January SE, Hubbard J, Fester KA, Dubrawka CA, Vazquez Guillamet R, Kulkarni HS, et al. Impact of Angiotensin Blockade on Development of Chronic Lung Allograft Dysfunction. Journal of Pharmacy Practice. 2024. doi:10.1177/08971900231213699

BibTeX
@article{January2024,
  author = {January, Spenser E and Hubbard, Julie and Fester, Keith A and Dubrawka, Casey A and Vazquez Guillamet, Rodrigo and Kulkarni, Hrishikesh S and Hachem, Ramsey R},
  title = {Impact of Angiotensin Blockade on Development of Chronic Lung Allograft Dysfunction},
  journal = {Journal of Pharmacy Practice},
  year = {2024},
  doi = {10.1177/08971900231213699}
}
Kostenlos starten →